Differentiation Between High- and Low-grade Astrocytoma Using a Human Recombinant Antibody to the Extra Domain-B of Fibronectin
Overview
Authors
Affiliations
Different fibronectin (FN) isoforms are generated by the alternative splicing of the primary FN transcript. We previously demonstrated that the isoform containing the extra domain B sequence of fibronectin (B-FN), a complete type-III-homology repeat, is a marker of angiogenesis that accumulates around neovasculature only during angiogenic processes. We produced a single-chain human recombinant antibody (scFv), L19, which reacts specifically with B-FN and selectively targets tumor vasculature in vivo. We used this scFv and an antibody against a pan-endothelial marker (Factor VIII) in a double-staining procedure on specimens of low- and high-grade astrocytomas to determine the percentage of B-FN-positive vessels, (denominating the resulting value angiogenic index [AI]). Compared to vascular density and proliferative activity (evaluated using antibodies to Factor VIII and Ki67, respectively), AI correlated better with tumor grade (1.6 +/- 2.6% and 92.0 +/- 8.7% of B-FN-positive vessels in low- and high-grade astrocytomas, respectively) and was a more precise diagnostic tool than either of the two conventional methods. In fact, discriminating analysis using these three parameters showed that only AI accurately classified 100% of the cases studied, compared to 64% and 89% correctly diagnosed by vascular density and of proliferating cells, respectively.
The impact of inflammation and acute phase activation in cancer cachexia.
Robinson T, Hamidi T, Counts B, Guttridge D, Ostrowski M, Zimmers T Front Immunol. 2023; 14:1207746.
PMID: 38022578 PMC: 10644737. DOI: 10.3389/fimmu.2023.1207746.
Zhang Z, Liu C, Wang M, Sun R, Yang Z, Hua Z J Immunother Cancer. 2023; 11(8).
PMID: 37586774 PMC: 10432677. DOI: 10.1136/jitc-2023-007199.
Nucleic acid drug vectors for diagnosis and treatment of brain diseases.
Lu Z, Shen J, Yang J, Wang J, Zhao R, Zhang T Signal Transduct Target Ther. 2023; 8(1):39.
PMID: 36650130 PMC: 9844208. DOI: 10.1038/s41392-022-01298-z.
CAR-T-Cell Therapy for Solid Tumors Positive for Fibronectin Extra Domain B.
Zhang Z, Liu C, Yang Z, Yin H Cells. 2022; 11(18).
PMID: 36139437 PMC: 9496916. DOI: 10.3390/cells11182863.
Hooper A, Marquette K, Chang C, Golas J, Jain S, Lam M Mol Cancer Ther. 2022; 21(9):1462-1472.
PMID: 35793468 PMC: 9446899. DOI: 10.1158/1535-7163.MCT-22-0099.